Tevogen Bio (TVGN) Competitors $0.74 +0.02 (+2.36%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. INBX, RAPT, CYRX, GLUE, PRTC, SLDB, ADCT, UPXI, KRRO, and AUTLShould you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Inhibrx Biosciences (INBX), Rapt Therapeutics (RAPT), CryoPort (CYRX), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Solid Biosciences (SLDB), ADC Therapeutics (ADCT), Upexi (UPXI), Korro Bio (KRRO), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Tevogen Bio vs. Its Competitors Inhibrx Biosciences Rapt Therapeutics CryoPort Monte Rosa Therapeutics PureTech Health Solid Biosciences ADC Therapeutics Upexi Korro Bio Autolus Therapeutics Inhibrx Biosciences (NASDAQ:INBX) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Do insiders & institutionals believe in INBX or TVGN? 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 17.1% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 73.2% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation & earnings, INBX or TVGN? Inhibrx Biosciences has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K2,463.77$1.69B-$10.58-3.22Tevogen BioN/AN/A-$13.73M-$0.19-3.89 Does the media prefer INBX or TVGN? In the previous week, Inhibrx Biosciences had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for Inhibrx Biosciences and 1 mentions for Tevogen Bio. Inhibrx Biosciences' average media sentiment score of 0.00 equaled Tevogen Bio'saverage media sentiment score. Company Overall Sentiment Inhibrx Biosciences Neutral Tevogen Bio Neutral Which has more risk & volatility, INBX or TVGN? Inhibrx Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -0.83, indicating that its stock price is 183% less volatile than the S&P 500. Is INBX or TVGN more profitable? Tevogen Bio's return on equity of 0.00% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -137.83% -76.31% Tevogen Bio N/A N/A -775.49% Do analysts rate INBX or TVGN? Tevogen Bio has a consensus price target of $10.00, indicating a potential upside of 1,251.35%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Tevogen Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryInhibrx Biosciences beats Tevogen Bio on 7 of the 13 factors compared between the two stocks. Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricTevogen BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$145.57M$12.30B$9.08B$10.58BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-3.8921.9786.1627.45Price / SalesN/A273.38539.92202.26Price / CashN/A47.1237.9261.55Price / Book-8.2210.2813.056.77Net Income-$13.73M-$52.40M$3.30B$275.88M7 Day Performance-5.06%6.10%4.55%2.63%1 Month Performance-16.37%15.74%9.73%9.10%1 Year Performance185.38%32.50%85.10%35.69% Tevogen Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNTevogen Bio2.3193 of 5 stars$0.74+2.4%$10.00+1,249.5%+130.6%$145.76MN/A-3.903Analyst ForecastINBXInhibrx Biosciences1.0171 of 5 stars$34.96-1.9%N/A+110.2%$506.40M$1.40M-3.30166News CoverageAnalyst ForecastRAPTRapt Therapeutics3.4906 of 5 stars$29.87-0.9%$23.50-21.3%+95.7%$493.99MN/A-2.1180Analyst ForecastCYRXCryoPort3.4212 of 5 stars$9.98+3.1%$12.56+25.8%+44.6%$484.65M$228.38M7.501,186Positive NewsAnalyst ForecastGLUEMonte Rosa Therapeutics2.1764 of 5 stars$7.66-1.0%$15.33+100.2%+54.2%$478.02M$75.62M21.2890Positive NewsAnalyst ForecastPRTCPureTech Health0.0773 of 5 stars$18.76-1.7%N/A-6.6%$461.13M$4.83M0.00100News CoverageAnalyst ForecastGap DownSLDBSolid Biosciences2.7649 of 5 stars$5.48-7.1%$15.00+173.7%-10.9%$459.43MN/A-1.96100News CoverageAnalyst ForecastADCTADC Therapeutics2.87 of 5 stars$4.43+8.6%$7.75+74.9%+47.9%$459M$70.84M-2.82310Analyst ForecastAnalyst RevisionGap UpHigh Trading VolumeUPXIUpexi2.7472 of 5 stars$7.70+3.5%$15.50+101.3%+173.7%$438.13M$15.81M0.00130Positive NewsKRROKorro Bio2.185 of 5 stars$43.70-5.5%$86.83+98.7%+30.8%$434.05M$6.28M-4.4870News CoveragePositive NewsAUTLAutolus Therapeutics3.537 of 5 stars$1.56-3.1%$9.12+484.6%-56.7%$428.49M$29.93M-1.86330Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Inhibrx Biosciences Competitors Rapt Therapeutics Competitors CryoPort Competitors Monte Rosa Therapeutics Competitors PureTech Health Competitors Solid Biosciences Competitors ADC Therapeutics Competitors Upexi Competitors Korro Bio Competitors Autolus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
